BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.12−0.03 (-2.61%)
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
BioLineRx's total debt was $4.48M at Jun 30, 2026. For fiscal 2025 it was $4.48M, up 0.0% from the year before. The highest annual figure on record is $4.48M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.48M | 0.0% |
| FY2024 | Dec 31, 2024 | $4.48M | +42.4% |
| FY2023 | Dec 31, 2023 | $3.15M | +104.0% |
| FY2022 | Dec 31, 2022 | $1.54M | -44.1% |
| FY2021 | Dec 31, 2021 | $2.76M | -10.8% |
| FY2020 | Dec 31, 2020 | $3.09M | +14.9% |
| FY2019 | Dec 31, 2019 | $2.69M | +200.8% |
| FY2018 | Dec 31, 2018 | $895.00K | +862.4% |
| FY2017 | Dec 31, 2017 | $93.00K | 0.0% |
| FY2016 | Dec 31, 2016 | $93.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.48M | -58.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.48M | +42.4% |
| Q2 FY2025 | Jun 30, 2025 | $4.48M | +45.5% |
| Q4 FY2024 | Dec 31, 2024 | $4.48M | +190.5% |
| Q2 FY2024 | Jun 30, 2024 | $10.66M | +951.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.15M | +14.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.08M | -8.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.54M | -50.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.01M | -64.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.76M | +2.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.35M | +40.0% |
| Q4 FY2020 | Dec 31, 2020 | $3.09M | +245.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.87M | +2982.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.69M | +2794.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.40M | +2475.3% |
| Q4 FY2018 | Dec 31, 2018 | $895.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $93.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $93.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $93.00K | – |
See a number that looks wrong?